Category Archives: Corporate

Wall Street Ponders Brexit’s Impact on Drug, Biotech Stocks

In a historic vote Thursday, Britain has decided to leave the European Union. And, swallowing hard, financial markets around the world are not taking the news very well. Stateside, the Dow… Read more »

Brexit Bargain Stocks Require Creative Mindset, Risk Tolerance

Frenzied bargain-hunters will immediately delve into the carnage of markets in the post-Brexit earthquake. Analysts advise caution but, more importantly, think creatively. The most obvious places to look are among… Read more »

Highmark Inc. is Seeking to Sell its Vision Unit

Highmark Inc. (Pittsburgh PA), which has lost about $773 million on the federal health insurance marketplace, is seeking to sell its vision unit, which could fetch around $2 billion. “We… Read more »

Specialty Medical Providers Envision, AmSurg to Merge

  Envision Healthcare Holdings Inc. (Greenwood Village CO) and AmSurg Corp. (Nashville TN) agreed to merge, in a deal that will create a company providing a range of hospital-related services worth some $10 billion. The… Read more »

First False Claims Act Settlement Turns on Cancer-Drug Survival Data

In the first False Claims Act settlement that turns on cancer-drug survival data, Roche Holding AG’s (Basel CHE) Genentech unit and OSI Pharmaceuticals LLC (Farmingdale NY) agreed to pay $67… Read more »

Glaxo Accelerates Regulatory Plan for Triple Combo Treatment for COPD

GlaxoSmithKline PLC (London) moved to consolidate its lead in a new class of three-in-one inhaled lung drugs on Thursday with plans to file its product for U.S. approval by the… Read more »

Clover Health Inc. Still a Favored to Disrupt the Trillion-Dollar Insurance Market

Clover Health Inc. (San Francisco) raised $160 million from private investors Friday, suggesting the sector is still a favorite among venture capitalists betting such startups can disrupt the trillion-dollar insurance… Read more »

Pfizer Acquires Anacor Pharma for $5.2 Billion

Pfizer Inc. (New York City) is buying Anacor Pharmaceuticals Inc. (Palo Alto CA) in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after… Read more »